Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.

Usmani SZ, Facon T, Hungria V, Bahlis NJ, Venner CP, Braunstein M, Pour L, Martí JM, Basu S, Cohen YC, Matsumoto M, Suzuki K, Hulin C, Grosicki S, Legiec W, Beksac M, Maiolino A, Takamatsu H, Perrot A, Turgut M, Ahmadi T, Liu W, Wang J, Chastain K, Vermeulen J, Krevvata M, Lopez-Masi L, Carey J, Rowe M, Carson R, Zweegman S

Open source

DOI: 10.1038/s41591-024-03485-7
Published: 2025 Apr
Container: Nature medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41591-024-03485-7,
  title = {Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.},
  author = {Usmani SZ and Facon T and Hungria V and Bahlis NJ and Venner CP and Braunstein M and Pour L and Martí JM and Basu S and Cohen YC and Matsumoto M and Suzuki K and Hulin C and Grosicki S and Legiec W and Beksac M and Maiolino A and Takamatsu H and Perrot A and Turgut M and Ahmadi T and Liu W and Wang J and Chastain K and Vermeulen J and Krevvata M and Lopez-Masi L and Carey J and Rowe M and Carson R and Zweegman S},
  year = {2025},
  journal = {Nature medicine},
  doi = {10.1038/s41591-024-03485-7},
  url = {https://doi.org/10.1038/s41591-024-03485-7}
}

RIS

TY  - JOUR
TI  - Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.
AU  - Usmani SZ
AU  - Facon T
AU  - Hungria V
AU  - Bahlis NJ
AU  - Venner CP
AU  - Braunstein M
AU  - Pour L
AU  - Martí JM
AU  - Basu S
AU  - Cohen YC
AU  - Matsumoto M
AU  - Suzuki K
AU  - Hulin C
AU  - Grosicki S
AU  - Legiec W
AU  - Beksac M
AU  - Maiolino A
AU  - Takamatsu H
AU  - Perrot A
AU  - Turgut M
AU  - Ahmadi T
AU  - Liu W
AU  - Wang J
AU  - Chastain K
AU  - Vermeulen J
AU  - Krevvata M
AU  - Lopez-Masi L
AU  - Carey J
AU  - Rowe M
AU  - Carson R
AU  - Zweegman S
PY  - 2025
JO  - Nature medicine
DO  - 10.1038/s41591-024-03485-7
UR  - https://doi.org/10.1038/s41591-024-03485-7
ER  -

APA

SZ, U., T, F., V, H., NJ, B., CP, V., M, B., L, P., JM, M., S, B., YC, C., M, M., K, S., C, H., S, G., W, L., M, B., A, M., H, T., A, P., M, T., T, A., W, L., J, W., K, C., J, V., M, K., L, L., J, C., M, R., R, C., & S, Z. (2025). Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.. Nature medicine. https://doi.org/10.1038/s41591-024-03485-7

Source records

pubmed · retrieved 2026-09-26T23:48:40.892Z